Novavax Inc

NVAX

Equity

ISIN null / Valor 47862952

NASDAQ (2026-08-04)

USD 7.66+3.37%

Novavax Inc
UMushroom community rating:

2.71 5 votes No rating yet

NegativeNeutralPositive

About company

Novavax Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Leveraging proprietary recombinant nanoparticle vaccine technology, Novavax has been at the forefront of developing vaccines for a range of infectious diseases, including its notable efforts in creating a vaccine for COVID-19. The company's approach combines the power of genetic engineering and nanoparticle technology to produce vaccine candidates aimed at eliciting robust immune responses. While the company has gained significant attention for its work during the COVID-19 pandemic, its research and development efforts extend to other infectious diseases as well, positioning Novavax as a key player in the global effort to combat emerging health threats through vaccination.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

13.5%1Y

-4.96%3Y

-96.6%5Y

Performance

67.2%1Y

92.3%3Y

101%5Y

Volatility

1260 M

Market cap (USD)

3,249,410

Daily traded volume (Shares)

8.2 / 7.7

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

2.71

5 votes

Performance:

3.14

Innovation:

3.29

Society:

3.57

Nature:

2.71

Nicolas Allet

Switzerland, 18 Mar 2026

Novavax faces ongoing financial headwinds as COVID demand fades. The Sanofi partnership offers a lifeline but uncertainty remains high. Protein subunit platform is differentiated yet commercialization beyond COVID is still unproven.